Literature DB >> 10580198

The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis.

N Solioz1, U Blum-Tirouvanziam, R Jacquet, S Rafati, G Corradin, J Mauël, N Fasel.   

Abstract

In a murine model of experimental cutaneous leishmaniasis, we investigated the protection elicited by injection of histone H1 isolated from parasites by perchloric extraction, of a H1 recombinant protein produced in E. coli, and of H1 long and short synthetic peptides, against infection by L. major. Partial protection was achieved in most of the animals as shown by reduction in lesion size, upon immunization with histone H1 or its peptides, provided that the region 1-60 was present in the molecule. These observations argue in favor of a thorough examination of the possibility of including histone H1 described here in a cocktail vaccine against human leishmaniasis.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10580198     DOI： 10.1016/s0264-410x(99)00340-0

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  10 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

4.  Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Authors:  Rhea N Coler; Yasir A W Skeiky; Karen Bernards; Kay Greeson; Darrick Carter; Charisa D Cornellison; Farrokh Modabber; Antonio Campos-Neto; Steven G Reed
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

5.  Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins.

Authors:  Maria Agallou; Evita Athanasiou; Olga Koutsoni; Eleni Dotsika; Evdokia Karagouni
Journal:  Front Immunol       Date:  2014-06-10       Impact factor: 7.561

6.  Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies.

Authors:  Rory C F Brito; Frederico G Guimarães; João P L Velloso; Rodrigo Corrêa-Oliveira; Jeronimo C Ruiz; Alexandre B Reis; Daniela M Resende
Journal:  Int J Mol Sci       Date:  2017-02-10       Impact factor: 5.923

7.  Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Authors:  J Moreno; J Nieto; S Masina; C Cañavate; I Cruz; C Chicharro; E Carrillo; S Napp; C Reymond; P M Kaye; D F Smith; N Fasel; J Alvar
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

8.  Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Marcia W Carneiro; Diego M Santos; Kiyoshi F Fukutani; Jorge Clarencio; Jose Carlos Miranda; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Manuel Soto; Camila I de Oliveira
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Design, Construction and Immunogenicity Assessment of pEGFP-N1-KMP11-GP96 (Fusion) as a DNA Vaccine Candidate against Leishmania major Infection in BALB/c Mice.

Authors:  Abdolhossein Dalimi; Vahid Nasiri
Journal:  Iran J Parasitol       Date:  2020 Jan-Mar       Impact factor: 1.012

10.  Vaccination in Leishmaniasis: A Review Article.

Authors:  Latifeh Abdellahi; Fariba Iraji; Anahita Mahmoudabadi; Seyed Hossein Hejazi
Journal:  Iran Biomed J       Date:  2022-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.